Asia-Pacific Deep Brain Stimulation Systems Market, By Product Type (Single-Channel Deep Brain Stimulator, Dual-Channel Deep Brain Stimulator), By Applications (Parkinson's disease, Epilepsy, Essential Tremor, Dystonia, Obsessive Compulsive Disorder and Other Applications), Type (Rechargeable, Non-Rechargeable), By End User (Neurological Clinics, Ambulatory Surgical Centers, Hospital and Others)– Industry Trends and Forecast to 2029
Market Analysis and Size
According to the World Health Organization, neurological diseases account for 6.3 percent of the Asia-Pacific disease burden and are one of the top causes of mortality, accounting for 13.2 percent of deaths in high-income countries and 16.8 percent in low- and middle-income countries. The high mortality and sickness load increase clinical urgency for long-term treatments such as deep brain stimulators. Furthermore, as the public becomes increasingly aware of the enormous burden of neurological disease, there is a greater demand for deep brain stimulators as an alternative therapy. This is projected to propel market expansion throughout the forecast period. Deep brain stimulators are being driven by the increasing occurrence of neurological disorders such as Parkinson's disease, essential tremors, dystonia, and epilepsy.
Data Bridge Market Research analyses that the deep brain stimulation systems market which was USD 1.22 billion in 2021, would rocket up to USD 6.95 billion by 2029, and is expected to undergo a CAGR of 24.3% during the forecast period 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2019 - 2014)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product Type (Single-Channel Deep Brain Stimulator, Dual-Channel Deep Brain Stimulator), Applications (Parkinson's disease, Epilepsy, Essential Tremor, Dystonia, Obsessive Compulsive Disorder and Other Applications), Type (Rechargeable, Non-Rechargeable), By End User (Neurological Clinics, Ambulatory Surgical Centers, Hospital and Others)
|
|
Countries Covered
|
China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC)
|
|
Market Players Covered
|
Boston Scientific Corporation (US), Fisher Wallace (US), SceneRay Corporation, Limited (China), Beijing PINS Medical Co., Ltd (China), ALEVA NEUROTHERAPEUTICS SA (Switzerland), MEDTRONIC (Ireland), and Abbott (US), Deep Brain Innovations, LLC (US), St. Jude Children's Research Hospital (US), Stanford Health Care (US), NeuroPace Inc. (US), Renishaw plc. (US), Functional Neuromodulation Ltd. (Canada)
|
|
Market Opportunities
|
|
Market Definition
Deep brain stimulation is a surgical procedure in which an electrical device is implanted in the brain. Electrical signals are sent from the gadget to the areas of the brain that govern movement. These devices are used to treat a variety of neurological diseases, including epilepsy, dystonia, Parkinson's disease, essential tremor, and obsessive-compulsive disorder.
Deep Brain Stimulation Systems Market Dynamics
Drivers
- Potential advantages of deep brain stimulation tools
Deep brain stimulation systems are projected to expand in popularity due to their long-term efficacy and better postoperative outcome control. Furthermore, these developments aid clinical researchers in using deep brain stimulation devices in experimental efficacy trials for the treatment of certain neurological diseases. Over the projected period, demand for deep brain stimulation devices is expected to rise due to these key causes.
-
Prevalence of lifestyle diseases
One of the initial factors driving the growth of the deep brain stimulation systems market is the rise in the incidence of lifestyle disorders such as depression and chronic pain around the world.
-
Rise in demand for minimal invasive surgery
The rising popularity of minimally invasive surgery among the general public, owing to benefits such as less pain and faster recovery, is propelling the industry forward.
- Occurrences of neurological disorders
The rise in neurological illnesses such as epilepsy, Parkinson's disease, Alzheimer's disease, and chronic pain is also having an impact on the market. Furthermore, severe adverse effects and medication interactions due to drug absorption by non-targeted locations are expected to drive demand for DBS devices. These medications can enhance motor function significantly, but they can also have side effects, especially as the disease advances. Constant treatment of the drug levodopa, for example, can lead to long-term problems such hallucinations, dyskinesia, neurotoxic consequences, and severe metabolic abnormalities. As a result of side effects like this, clinicians are increasingly turning to specialised therapy options, such as deep brain stimulators. As a result, market growth will be boosted during the forecast period.
Opportunities
Technical improvements in deep brain stimulation technologies are expected to propel this market forward. Robot-assisted insertion, improved microelectrode designs, multi-target stimulation, rechargeable implantable pulse generators, and tailored directed programming are among the technological advancements. As a result of these developments, DBS devices are demonstrating less side effects, increased efficacy, and symptomatic alleviation in Parkinson's patients compared to previous techniques. The Infinity Deep Brain Stimulation (DBS) System from Abbott, for example, is a highly advanced new DBS that can aid patients with their symptoms. It's the world's first wireless iOS software DBS mobile platform, allowing for more efficient and tailored therapy administration with fewer side effects.
Further advancements in fundamental neuroscience and other disciplines of research and technology are anticipated to broaden DBS' therapeutic application. DBS demonstrates an extremely obvious link between basic science, clinical research, and therapeutic practise, making it highly fascinating from both a humanitarian and a scientific standpoint. As with any new field of research, there are possible problems ahead, but DBS holds a lot of promise, and there's reason to expect that the next 50 years of progress will provide even more benefits than the prior 50.
Restraints/Challenges
Concerns about side effects such as allergic response and tingling or prickling of the skin, on the other hand, are predicted to stymie market expansion. In the forecast period of 2022-2029, other treatment options, such as medication therapy and surgeries, are expected to pose a challenge to the deep brain stimulation systems market. Financial constraints also hamper DBS research and wider clinical usage. Because the hardware and the surgery and follow-up consultations are costly, large-scale trials can be difficult to fund. Due to a lack of large-scale trial data, funding authorities are hesitant to pay for DBS, resulting in fewer patients to examine.
This cost issue is especially troublesome in underdeveloped countries, where few people can afford the hardware and treatment costs despite a high frequency of movement disorders and other illnesses that may be treated with DBS. Although the absence of surgical facilities and experience may still be a limiting factor, further development of low-cost IPGs might help alleviate this difficulty.
This deep brain stimulation systems market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the deep brain stimulation systems market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Deep brain stimulation systems Market
The outbreak of COVID-19, medical services such as deep brain stimulation saw a drop in revenue in 2020 and 2021. During the pandemic, major medical procedures were postponed to avoid the transmission of the coronavirus. However, due to the easing of restrictions, a rise in deep brain stimulation procedures is expected in the post-COVID period. The impact of Covid-19 on Parkinson's disease (PD) patients could be studied in terms of its impact on PD patients' health and their risk of developing severe Covid-19 and the mental and cognitive effects of lockdown restrictive measures on both patients and caregivers. Furthermore, there are significant considerations to address about patient care and management during this unusual period. Physiotherapy is a vital consideration, as most patients are unable to exercise due to restrictive restrictions that have had a significant influence on their health. Finally, the link between PD and Sars-Cov2 may be more convoluted than it appears, as some investigations have suggested that Covid-19-induced parkinsonism may exist.
Recent Development
- Jan-2020: The Percept PC neurostimulator from Medtronic has received the CE mark. BrainSense technology is used in this Deep Brain Stimulation (DBS) device. Patients with neurologic illnesses such as Parkinson's disease can benefit from the system's ability to detect and record brain signals while receiving treatment.
- Jan-2020: The US Food and Drug Administration (FDA) has approved Abbott Laboratories' Infinity Deep Brain Stimulation (DBS) device. This system would be employed in Parkinson's disease treatment. The technology would allow for the improvement of Parkinson's disease symptoms that are not controlled by medication by targeting a specific area of the brain known as the internal globus pallidus (GPi).
Asia-Pacific Deep Brain Stimulation Systems Market Scope
The deep brain stimulation systems market is segmented on the basis of product, type, application and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product Type
- Single-Channel Deep Brain Stimulator
- Dual-Channel Deep Brain Stimulator
Type
- Rechargeable
- Non-Rechargeable
Applications
- Parkinson's disease
- Epilepsy
- Essential Tremor
- Dystonia
- Obsessive Compulsive Disorder
- Other Applications
End-User
- Neurological Clinics
- Ambulatory Surgical Centers
- Hospital
- Others
Deep Brain Stimulation Systems Market Regional Analysis/Insights
The deep brain stimulation systems market is analysed and market size insights and trends are provided by country, product, type, application and end-user as referenced above.
The countries covered in the deep brain stimulation systems market report are China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC).
North America dominates the deep brain stimulation systems market because of the rise in the number of PD patients coupled with increasing government funding and initiatives within the region.
Asia-Pacific (APAC) is expected to witness substantial growth during the forecast period of 2022 to 2029 due to the increase in occurrence of neuro degenerative disorders in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed base and New Technology Penetration
The deep brain stimulation systems market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for deep brain stimulation systems market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the deep brain stimulation systems market. The data is available for historic period 2010-2020.
Competitive Landscape and Deep Brain Stimulation Systems Market Share Analysis
The deep brain stimulation systems market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Asia-Pacific presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to deep brain stimulation systems market.
Some of the major players operating in the deep brain stimulation systems market are:
- Boston Scientific Corporation (US)
- Fisher Wallace (US)
- SceneRay Corporation, Limited (China)
- Beijing PINS Medical Co., Ltd (China)
- ALEVA NEUROTHERAPEUTICS SA (Switzerland)
- MEDTRONIC (Ireland)
- Abbott (US)
- Deep Brain Innovations, LLC (US)
- St. Jude Children's Research Hospital (US)
- Stanford Health Care (US)
- NeuroPace Inc. (US)
- Renishaw plc. (US)
- Functional Neuromodulation Ltd. (Canada)
SKU-